RLMD Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Relmada Therapeutics's net margin of 8.48%. Relmada Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Relmada Therapeutics has a consensus price target of $10.88, signalling upside risk potential of 138.69%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Relmada Therapeutics has higher upside potential than Eli Lilly and, analysts believe Relmada Therapeutics is more attractive than Eli Lilly and.

Relmada Therapeutics has a beta of 0.353, which suggesting that the stock is 64.671% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Relmada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Relmada Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Relmada Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Relmada Therapeutics's net income of -$21.7M is lower than Eli Lilly and's net income of $970.3M. Notably, Relmada Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics is -- versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Relmada Therapeutics's net margin of -49.65%. Relmada Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Relmada Therapeutics has a consensus price target of $10.88, signalling upside risk potential of 138.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Relmada Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Relmada Therapeutics.

Relmada Therapeutics has a beta of 0.353, which suggesting that the stock is 64.671% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Relmada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Relmada Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Relmada Therapeutics's net income of -$21.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Relmada Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Relmada Therapeutics's net margin of -2357.27%. Relmada Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Relmada Therapeutics has a consensus price target of $10.88, signalling upside risk potential of 138.69%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Relmada Therapeutics, analysts believe Palatin Technologies is more attractive than Relmada Therapeutics.

Relmada Therapeutics has a beta of 0.353, which suggesting that the stock is 64.671% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Relmada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Relmada Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Relmada Therapeutics's net income of -$21.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Relmada Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sensei Biotherapeutics has a net margin of -- compared to Relmada Therapeutics's net margin of --. Relmada Therapeutics's return on equity of -- beat Sensei Biotherapeutics's return on equity of --.

Relmada Therapeutics has a consensus price target of $10.88, signalling upside risk potential of 138.69%. On the other hand Sensei Biotherapeutics has an analysts' consensus of -- which suggests that it could grow by 816.87%. Given that Sensei Biotherapeutics has higher upside potential than Relmada Therapeutics, analysts believe Sensei Biotherapeutics is more attractive than Relmada Therapeutics.

Relmada Therapeutics has a beta of 0.353, which suggesting that the stock is 64.671% less volatile than S&P 500. In comparison Sensei Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Relmada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensei Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics pays -- of its earnings as a dividend. Sensei Biotherapeutics pays out -- of its earnings as a dividend.

Relmada Therapeutics quarterly revenues are --, which are smaller than Sensei Biotherapeutics quarterly revenues of --. Relmada Therapeutics's net income of -$21.7M is lower than Sensei Biotherapeutics's net income of -$7.3M. Notably, Relmada Therapeutics's price-to-earnings ratio is -- while Sensei Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics is -- versus -- for Sensei Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.